Jenkins is being disingenuous imo. Farkas, Unger, etc handpicked that adcom to fit their agenda. And then they collectively got exposed for having no real expertise or even understanding on dmd and they were called out for it. Now he has sour grapes. So his hand picked lackeys now may be hesitant to serve his needs in the future? What a hardship for Jenkins!! My advice for him- next time recruit some actual experts for a dnp adcom.......
But both target Dystrophin expression, altho in different ways. I will admit i dont fully understand how overlapping (or not) the two approaches are. I do understand they target different genetic populations but i was under the impression there could be overlap in prescriptions
It was my understanding as SRPT develops all its exon drugs, ataluren could be competively prescribed. Is that incorrect? If not pls explain
Ed couldnt have been more clear that this deal w SMMT was forthcoming, he gave us a great buying opportunity. I like the deal, smart move. Imo Ed made a much bigger bet on SMMT than he did on Catb. We shall see....
Sentiment: Strong Buy
Its all about perspective. Srpt closed at 48 the day AA was announced. Now it is about 25% higher. The trend is strong. If the trend is strong the stock is pretty strong
I personally like smmt chances better than catb. But they both are longshots imo. Srpt is obviously a sure thing for revenue, the other dmd players cant say that at all
I would be careful on the whole pumping catb thing. As far as i know srpt committed no $ to catb and arent they (in terms of the collaboration) only looking at mouse models, not humans- for basically a steroid equivalent? Look at the action yesterday, people were locking in profits on srpt and rolling it into catb . Be careful what you wish for !!
There have been filings for who bought into the recent offering, and how much of the over allotment. Check it out its impressive #s, these people can and will protect this investment
Price will be slight discount to todays closing. We shall see
Upgrading SRPT in the next couple months? Not bad. Compare Goldman Sacs, JP Morgan and Credit Suisse to the outfits covering srpt now, lol
I would guess a very significant portion of those short from 15-25 have covered,, only to be replaced by new short positions in the 46-56 range. No worries i have no prob with shorts, if i have conviction in my position, i need someone on the other side of the trade